From Academia To The Biopharma C-Suite
Source: Life Science Leader
Not everyone pursues the completion of a doctoral degree with the mindset of becoming a college professor. However, there are many who do. And while this tends to happen less so in the life science space when compared to that of other disciplines, it does still happen. As such, we thought an executive virtual roundtable topic of, “From Academia To The Biopharma C-Suite,” would enable us to learn from those taking a less traditional path to becoming a biopharmaceutical executive. In this executive virtual roundtable (EVR), perspectives are provided by Rahul Aras, Ph.D., CEO, Iterion Therapeutics; Steffen Mueller, Ph.D., cofounder and CSO, Codagenix; and Prem Premsrirut, M.D., Ph.D., CEO, Mirimus.
This website uses cookies to ensure you get the best experience on our website. Learn more